Article

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)

2024-08-05

Abstract excerpt

<h4> Abstract </h4> Genetic obesity such as Prader Willi syndrome (PWS) is a multifaceted condition influenced by various elements, including genetic predisposition, environmental factors, and behavioral components. This meta-analysis explored the reported efficacy of therapeutics in clinical trials for PWS by evaluating clinical endpoints reached in the course of the study and the adverse events observed for each...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef322483-df0f-5ae8-912d-92099026e13a
DOI: 10.1101/2024.08.02.24311335

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)DOI 10.1101/2024.08.02.24311335Read

Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndromeSemantic proximity Read

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read

Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight lossSemantic proximity Read

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomizationSemantic proximity Read

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity Read

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read

From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?Semantic proximity Read

Disentangling ingestive behavior-related phenotypes in Prader-Willi syndrome: Integrating information from nonclinical studies and clinical trials to better understand the pathophysiology of hyperphagia and obesity.Semantic proximity Read

Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity Read

Pharmacogenomics of Anti-Obesity Drugs: A Bioinformatics ApproachSemantic proximity Read